CCM2 and cerebral cavernous malformation: Using in vitro transcellular resistance analyses, dermal permeability assays in inducible endothelial-specific Ccm2 knockout mice, and magnetic resonance imaging as secondary, tertiary, and quaternary screens, they identified tempol and cholecalciferol as promising candidates for CCM therapy [36].